Oxygen Biotherapeutics (OBI) has announced the commencement of patient enrolment in the second cohort of its Phase IIb trial of Oxycyte in Israel.

The Phase IIb clinical trial will investigate the safety and tolerability of Oxycyte in patients with severe, non-penetrating traumatic brain injury (STOP-TBI).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

OBI president and chief financial officer Michael Jebsen said enrolment in the second cohort is a major milestone in Oxycyte’s development.

"We have spent the last year focused on securing long-term supply of clinical trial material and retaining a contract research organisation with the ability to effectively manage an international clinical trial," Jebsen said.

"The Phase IIb clinical trial will investigate the safety and tolerability of Oxycyte in patients with severe, non-penetrating traumatic brain injury."

"Bringing Oxycyte to market as a treatment for acute ischemic conditions, such as TBI, remains the top priority of OBI."

See Also:

The randomised, double-blind study administers oxycyte once intravenously to patients, along with supplemental oxygen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary objective of the placebo-controlled dose-escalation study is to assess the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury.

The secondary objective is to assess the potential of Oxycyte in improving the severity of TBI.

The Glasgow Outcome Scale – Extended (GOS-E) will measure the functional status of patients.

The STOP-TBI study will enrol an additional 68 subjects at up to 18 sites in Israel, Switzerland, France and Spain.